CGH and Hyflux to study effectiveness of ELO Water

20 February 2017 | ResearchAcademic Medicine 

Dr Lee Chien Earn, CEO of CGH, and Ms Olivia Lum, Executive Chairman and Group CEO, Hyflux, signed the clinical trial agreement on 15 February 2017.

Hyflux, the company known for their water desalination plants, has tied up with Changi General Hospital (CGH) to conduct the first human clinical trials of the company's ELO Water on Type-2 diabetes.

The trials are led by Dr Joan Khoo, Senior Consultant and Chief of Endocrinology at CGH. They will study whether drinking ELO Water in addition to ongoing treatments can help patients control their blood sugar level better, and whether applying ELO Gel can accelerate wound healing in diabetic foot ulcers.

ELO Water is Hyflux's oxygen-rich water that is believed to enhance health and overall well-being. Animal trials conducted overseas have shown positive benefits of ELO Water. One such study by Monash University, Australia, showed cancer-inhibiting effects in mice through increase in oxygen levels in tumours.

Dr Lee Chien Earn, CEO of CGH, said, "Diabetes is a significant public health concern for Singapore. Hyflux has come to us with an interesting hypothesis based on animal studies that could help our patients with diabetes. We have thus embarked on this research collaboration to test this hypothesis in a robust scientific way."

Hyflux is committing up to S$2.5 million in cash and in kind to human clinical trials to further ascertain the scientific merits of its ELO Water.

"If the trials are successful, it will ultimately improve the quality of life for diabetic patients," said Ms Olivia Lum, Executive Chairman and Group CEO, Hyflux.

Related news